Back to Resource Library
Advocates’ Primer: Understanding Bioequivalence and Pharmacokinetic Studies in Next-Generation HIV Prevention Products
As more next-generation PrEP options become available, HIV prevention research is shifting away from large, multi-year efficacy trials toward pharmacokinetic (PK) and bioequivalence (BE) studies — which test whether a new formulation behaves in the body like a product already proven to work. This primer explains the shift and what it means for advocates.